Cancer Immunotherapy: How Checkpoint Inhibitors and Emerging Therapies Are Redefining Oncological Treatment

Introduction

Cancer immunotherapy has fundamentally transformed the landscape of oncological treatment over the past decade, shifting from an experimental concept to a cornerstone of modern cancer care. Unlike traditional chemotherapy, which directly attacks rapidly dividing cells, immunotherapy harnesses the body's own immune system to recognise, target, and destroy cancer cells. This paradigm shift has delivered unprecedented survival benefits across a growing number of cancer types and has opened new therapeutic possibilities for patients who previously had limited treatment options.

In 2024 alone, the United States Food and Drug Administration (FDA) granted 17 new immunotherapy approvals, and by December 2025, over 70% of the 52 oncology drug approval announcements involved immunotherapy or targeted therapy agents. These numbers reflect not merely the volume of new treatments but the remarkable diversification of immunotherapeutic mechanisms now available to oncologists worldwide.

Understanding Cancer Immunotherapy

The immune system possesses a natural ability to detect and eliminate abnormal cells, including cancer cells. However, tumours have evolved sophisticated mechanisms to evade immune surveillance. Cancer immunotherapy works by disrupting these evasion strategies, effectively "releasing the brakes" on the immune system or "pressing the accelerator" to enhance anti-tumour responses.

Immune Checkpoint Inhibitors (ICIs) represent the most widely used class of immunotherapy drugs. These agents block inhibitory receptors on immune cells — most notably PD-1, PD-L1, and CTLA-4 — that tumours exploit to suppress immune attack. By blocking these checkpoints, the drugs restore the immune system's ability to recognise and destroy cancer cells. Checkpoint inhibitors have demonstrated remarkable efficacy in melanoma, non-small cell lung cancer (NSCLC), bladder cancer, renal cell carcinoma, head and neck cancers, and an expanding list of other malignancies.

CAR-T Cell Therapy involves genetically engineering a patient's own T cells to express chimeric antigen receptors (CARs) that specifically target proteins on the surface of cancer cells. This personalised approach has achieved extraordinary response rates in certain blood cancers, with some patients achieving complete and durable remissions.

Bispecific Antibodies are engineered proteins that simultaneously bind to a tumour antigen and an immune cell receptor, physically bridging cancer cells and immune effector cells to facilitate targeted killing.

Cancer Vaccines aim to train the immune system to recognise tumour-specific antigens. The field gained significant momentum in 2024–2025 with major advances in mRNA-based cancer vaccines for pancreatic and brain cancers, supported by over 120 ongoing clinical trials.

Clinical Evidence: Landmark Outcomes

The clinical impact of immunotherapy has been validated by numerous large-scale trials. A comprehensive analysis presented at the American Society of Clinical Oncology (ASCO) in September 2024 demonstrated that immunotherapy improves long-term survival across a growing number of cancers. The five-year overall survival rate reached 86.6% in patients receiving immunotherapy compared with 81.7% in the placebo group — a clinically meaningful improvement that translates to thousands of additional life-years saved.

For specific cancer types, the outcomes have been even more striking:

The evolution from treating only advanced, metastatic disease to incorporating immunotherapy in earlier stages (neoadjuvant and adjuvant settings) represents another major paradigm shift. Clinical trials have shown that administering checkpoint inhibitors before surgery can shrink tumours, improve surgical outcomes, and reduce recurrence rates.

Hong Kong's Role in Cancer Immunotherapy

Hong Kong has positioned itself at the forefront of immunotherapy research and clinical application in Asia. Several developments highlight the city's commitment to advancing cancer care:

The University of Hong Kong (HKU) research team developed an innovative vascularised tumour model in October 2025 that provides a powerful new platform for researching cancer and testing immune cell therapies. This breakthrough enables more accurate preclinical evaluation of immunotherapy candidates before they enter human trials.

In March 2026, researchers at the Chinese University of Hong Kong (CUHK) announced the discovery of a "super cancer killer" cell through artificial intelligence-guided research. While conventional immunotherapy can be highly effective against certain blood cancers, it has been far less effective against solid tumours with dense microenvironments. This AI-driven discovery offers potential solutions to one of immunotherapy's most persistent challenges.

Hong Kong also introduced the most extensive data platform for advancing cancer immunotherapy research in October 2025, facilitating collaboration among researchers and accelerating the translation of laboratory discoveries into clinical treatments.

For GCC patients, Hong Kong's oncology centres offer access to the latest approved immunotherapy agents, participation in cutting-edge clinical trials, and multidisciplinary tumour board reviews that ensure each patient receives a personalised treatment strategy. The city's oncologists maintain close ties with leading cancer centres worldwide, ensuring that treatment protocols reflect the most current evidence.

Managing Side Effects

While immunotherapy is generally better tolerated than traditional chemotherapy, it carries a unique spectrum of side effects known as immune-related adverse events (irAEs). Because these drugs activate the immune system broadly, they can occasionally trigger inflammation in healthy organs — most commonly the skin, gastrointestinal tract, liver, lungs, and endocrine glands.

Early recognition and prompt management of irAEs are essential. Hong Kong's oncology teams are highly experienced in monitoring for these events and implementing evidence-based treatment protocols, which typically involve corticosteroids or other immunosuppressive agents. With proper management, the vast majority of irAEs are reversible and do not require permanent discontinuation of immunotherapy.

Who May Benefit from Immunotherapy?

Immunotherapy is not a one-size-fits-all treatment. The likelihood of response depends on several factors, including the tumour's molecular profile (particularly PD-L1 expression and microsatellite instability status), the cancer type and stage, the patient's overall health and immune function, and prior treatment history.

Biomarker testing has become an essential component of treatment planning. Tumour genomic profiling can identify patients most likely to benefit from specific immunotherapy agents, enabling a truly personalised approach to cancer care. Hong Kong's pathology laboratories are equipped with the latest molecular diagnostic technologies to perform these critical assessments.

Conclusion

Cancer immunotherapy has ushered in a new era of oncological treatment, delivering survival benefits that were unimaginable just a decade ago. The rapid pace of innovation — from checkpoint inhibitors to CAR-T cells to mRNA vaccines — continues to expand the therapeutic landscape. Hong Kong's combination of world-class research institutions, experienced oncologists, and access to the latest treatments makes it an ideal destination for GCC patients seeking cutting-edge cancer care. As the field continues to evolve, the promise of immunotherapy to transform cancer from a terminal diagnosis into a manageable or even curable condition grows ever closer to reality.